Heron Therapeutics, Inc. (HRTX) Earnings Call Transcript & Summary
August 9, 2022
Earnings Call Speaker Segments
David Szekeres
executiveHello, everybody, and welcome — we appreciate you being here this afternoon. Joining me on today's call are two people from Heron: Barry Quart, who serves as Chief Executive Officer and Chairman, along with John Poyhonen, our President and Chief Commercial Officer. If you're on the conference call, the slides can be viewed through the webcast, and after today's call wraps up, you can also find them on the investor relations section of our website. Prior to getting started, please bear in mind that forward-looking statements regarding Heron's future expectations, plans, prospects, corporate strategy, and performance will be part of this call, and these qualify as forward-looking statements under the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. Various important factors, including those covered in our SEC filings, could cause actual results to differ materially from what these forward-looking statements indicate. The views expressed in any forward-looking statements reflect only what we think as of the date of this webcast and shouldn't be relied upon as representing our views at any later date. We specifically disclaim any obligations to update such statements. I'll now hand the call over to Barry.
Barry Quart
executiveThanks, David. Hello, everyone, and I appreciate you being with us. On many fronts, the second quarter proved highly productive. John is going to walk through specifics about our two commercial franchises, and each delivered solid growth in Q2 while surpassing consensus expectations. Throughout Q2, we kept advancing our NDA for HTX-019 in postoperative nausea and vomiting, a market that could be far bigger than our CINV business by multiple times. Our dealings with the FDA are still progressing toward the September 17 PDUFA date. We have likewise achieved strong momentum in finishing enrollment across the four clinical trials involving ZYNRELEF that are slated for inclusion in what we refer to as sNDA number two, which is intended to broaden the indications for ZYNRELEF even further; that sNDA is scheduled for later this year. Under our arrangement with the FDA, sNDA two ought to serve as the foundation for widening the indication statement so it encompasses basically all 14 million target procedures. At this point, I will hand the call over to John.
John Poyhonen
executiveThank you, Barry. It's a pleasure to walk you through our commercial performance for the second quarter. With the ZYNRELEF launch, we keep achieving meaningful headway. Over the course of my remarks, I'll begin by covering several developments concerning the key performance metrics tied to that headway. Then I'll wrap up with news about the excellent commercial results we delivered in Q2 through our oncology care business. Net sales for Q2 came in at $2.5 million, representing growth of 140% versus the quarter before; at present, we anticipate that ZYNRELEF net product sales for Q3 will rise somewhere in the 40%-50% range compared with the previous quarter. How much ZYNRELEF inventory sits in the distribution channel has drawn considerable attention across the last few quarters. As we explained on earlier earnings calls, the distribution channel had been carrying excess initial stocking inventory. To get a clearer read on how much inventory the distribution channel holds, we have been disclosing the ex-factory reorder rate, calculated on demand unit volume, for the two SKUs. Our ultimate aim is for ex-factory orders to equal 100% of demand unit volume — that is, for each unit sold to a hospital or ASC, the distribution channel replenishes its inventory accordingly. Looking at slide six's table, you can see we're continuing to make significant progress clearing that inventory, and that's being fueled by stronger demand unit sales for ZYNRELEF. According to data covering Q3 through August 3, we've achieved what we set out to do — stabilizing inventory at the distribution centers — and channel orders are now moving in line with demand unit results. On the 400 mg SKU, reorders equal 99% of demand unit volume, and on the 200 mg SKU, that figure comes in at 105%. With this in place, modeling ZYNRELEF net sales going forward should become simpler, with those levels aligning with ZYNRELEF demand unit volume. Compared with Q3, ZYNRELEF demand unit volume was up 47% in Q2. So far in Q3, ZYNRELEF demand units are running ahead of the equivalent stretch of Q2, and we expect to deliver 40%-50% growth in Q3. Now I'll recap the ZYNRELEF launch highlights so far by walking through our scorecard of leading indicators. Across our initial year of launch, we have maintained a strong pace of bringing on unique new ordering accounts, which have been increasing by roughly 50 accounts each month. We also feel pretty good about the improvement in account reorder rates—they went up from 50% in the first three months after launch to 84% in the first year. We continue to lock in formulary approvals for ZYNRELEF at the hospitals we're targeting, and since launch we've been averaging 30 formulary approvals per month. On top of that, we're seeing really strong expansion among integrated delivery networks, or IDNs, that put ZYNRELEF on formulary. From where we sit, getting IDN backing matters a lot for possible therapeutic interchanges, since later on our key accounts may switch from EXPAREL to ZYNRELEF for the procedures where it's indicated. Slide nine uses Symphony Health data to show how many unique ordering accounts there were in the first year after launch. We keep bringing on new accounts that order ZYNRELEF at a fast pace, reaching 602 ordering accounts within the first 12 months after launch. That's a 33% gain over the 451 level seen in the first nine months after launch. On top of that, for ZYNRELEF, the 84 accounts that reordered in year one mark the highest reorder percentage among all four products used as benchmarks in this analysis. We see this rising reorder rate as a great sign of the solid real-world experience surgeons are having with their patients. Although the early ZYNRELEF results are strong, pushing aggressive expansion and product usage within ordering accounts is a key priority for 2022. New formulary approvals make up our new business pipeline; this slide shows the continued fast progress ZYNRELEF is making on formulary approvals. At the close of April, we reported 319 formulary approvals. Since launch, that figure has kept climbing by roughly 30 new formulary approvals each month, reaching 384 total approvals through the end of July. Among those accounts actually making P&T decisions, more than 90% of hospital P&T committees keep adding ZYNRELEF to formulary. Importantly, an estimated 68% of our formulary approvals cover unrestricted usage of ZYNRELEF. Accounts with restricted usage usually limit the procedures for their internal trial evaluations of the product. Many institutions scaled back P&T meetings during the summer because of vacation schedules. We expect the remaining months to be quite active—over 80 more P&T committees are lined up to evaluate ZYNRELEF prior to year-end. Securing additional formulary wins enables us to establish an essential pipeline for fresh ZYNRELEF business, and that remains a major focus for our commercial organization. Turning to another point, I'd like to share progress on an important top-down approach: focusing on integrated delivery networks, or IDNs, so we can unlock new system-wide chances to drive therapeutic interchange from EXPAREL to ZYNRELEF for procedures where it's indicated. To date, ZYNRELEF has been placed on formularies at 57 IDNs, and 33% of those approvals permit unrestricted use. Also, those 57 IDNs represent more than a million ZYNRELEF indicated procedures each year, which works out to a possible $200 million in yearly ZYNRELEF net sales if every indicated procedure were converted. Obviously, achieving a full 100% share is unrealistic for any company, yet the upside tied to our current indicated procedures still opens a substantial path toward significant ZYNRELEF sales growth. Beyond that, our IDN formulary expansion now spans $135 million in annual EXPAREL sales. On top of this, 15 IDNs are at different points in assessing a switch from EXPAREL to ZYNRELEF for procedures that are indicated. Let's now take a closer look at those 15 IDNs showing interest in a possible therapeutic interchange. Given that ZYNRELEF now carries a broader label indication, it makes sense that IDNs want to achieve savings in the millions of dollars with a product that has proven clinically superior to bupivacaine, the current standard of care. We're thrilled to collaborate with pharmacists and physicians alike as they conduct their internal assessments of ZYNRELEF. Out of the 15 IDNs expressing interest, 11 have already begun their own internal trials involving ZYNRELEF. So far, feedback from these trials has been highly encouraging and covers a wide range of surgical procedures. While shifting a large IDN certainly takes time, the first IDN to arrive at a therapeutic interchange decision wrapped up Q2 on a strong note, and as of today, that organization is making the switch to ZYNRELEF. This quarter brings a fresh metric we're adding to assess the effect we're having with IDNs. Let's begin by looking closely at the 15 IDNs currently evaluating therapeutic interchange. Across the first half of 2022, demand units for ZYNRELEF climbed 290% versus the second half of 2021. Plainly, our broader label indication is driving that expansion. Another new measurement we're adding is branded market share. The calculation is straightforward: ZYNRELEF units divided by total EXPAREL units plus ZYNRELEF units. On the whole, among the 57 IDNs holding formulary approval, we've shown strong growth in branded market share. One thing to remember is that bringing on additional IDNs actually pushes our share down, because we are only starting to generate new ZYNRELEF business within those accounts. To illustrate, during the prior quarter we reported 46 IDNs with formulary approvals, a figure that has since risen to 57 IDNs. Lastly, we've also shared ZYNRELEF's branded unit market share for the top 5 IDN share accounts among those 15 IDNs evaluating a therapeutic interchange from EXPAREL to ZYNRELEF.
John Poyhonen
executiveAs this table shows, our branded market share is capable of rising quite rapidly, reaching a peak of 41% in Q2. CMS granting passthrough status so that ZYNRELEF gets separate reimbursement for Medicare patients in the hospital outpatient care setting changes everything for us. To reiterate, over the coming three years, ZYNRELEF stands alone as the local anesthetic that is separately reimbursed in the hospital outpatient setting. This significant approval adds to the reimbursement advantages we already had in place. CMS provides separate reimbursement for ZYNRELEF in the ASC care setting starting January 1, 2022. ZYNRELEF is reimbursed apart from the surgical bundle payment, with over 123 million covered lives in ASC, and in certain instances, it is likewise reimbursed separately in the hospital outpatient setting. One essential element of how we set prices is that even absent separate reimbursement, our lower acquisition cost helps customers in every care setting where the drug might be paid for through the surgical bundle payment. ZYNRELEF's value proposition keeps serving as a vital engine for new business and market expansion. Making the switch to ZYNRELEF delivers a cost savings of 25%-32% according to wholesale acquisition cost, plus a savings of 42%-48% according to our 340B price offering when compared with EXPAREL. That creates an enormous financial incentive for customers to move to ZYNRELEF. Looking at it from a reimbursement angle, using ZYNRELEF is profitable with Medicare patients in the hospital outpatient setting and the ASC care setting. Amid these difficult financial times, 340B accounts can see a financial benefit exceeding $429 per patient by choosing ZYNRELEF instead of EXPAREL. Given these economic benefits, it comes as no surprise that large IDNs are now performing therapeutic interchange evaluations. From a commercial standpoint, our key priorities for ZYNRELEF in 2022 stay unchanged. Our top priority is to take advantage of the new label indications to grow faster. We will achieve this by extending existing surgeon usage into new procedures. Our second priority is to boost usage within ordering accounts by raising the number of surgeons who routinely use ZYNRELEF. Many accounts first evaluated ZYNRELEF with just two or three surgeons, based on the excellent outcomes with their patients who are actively using their experience to support expanded usage of ZYNRELEF with their colleagues. Our third priority is to keep securing formulary approvals in new targeted IDNs and hospitals. Greater access in our pipeline is a key opportunity for growth and therapeutic interchange. Last, we keep maximizing our separate reimbursement outside of the surgical bundle payment for ZYNRELEF; in summary, we have already achieved strong progress on a number of leading indicators, which gives us confidence that 2022 will be a year of significant growth for ZYNRELEF. Now I want to change direction and go over the Q2 results for our oncology care franchise. During the Q2, our oncology care team did an outstanding job of growing our CINV portfolio net sales by 12% over the prior year. The increase came from CINVANTI rising 11% and SUSTOL rising 18% versus the previous quarter. On the whole, CINVANTI unit demand climbed almost 11% from the quarter before, including a solid 11% gain in the hospital setting of care, which stood as our third largest demand unit quarter ever for the hospital segment. CINVANTI demand units also stayed robust in the clinic setting of care, rising 10% against the prior quarter. We are holding a number of ongoing discussions aimed at winning back former CINVANTI customers now that the generic fosaprepitant arbitrage period has ended. Our CINV products outlook stays positive, supported by reimbursement tailwinds that have kept improving over the past year. As the table on slide 21 shows, both CINVANTI and SUSTOL now sit in a far more favorable reimbursement position relative to the competition than they did at the same point last year, with generic fosaprepitant falling to $27 and IV Emend falling to $458 under ASP + 4% reimbursement. Beyond that, separate reimbursement for generic fosaprepitant in the hospital outpatient segment was eliminated as of January 1, 2022, which made the CINVANTI value proposition considerably more compelling this year. Our full year 2022 CINV net sales guidance has been raised to a range of $93 million-$95 million, which represents an 11%-14% gain over the prior year; we also anticipate that demand units in the H2 of 2022 will exceed the prior year, partially offset by lower net sales for both products. Lastly, new CMS guidelines issued in July stated that as of January 1, 2023, reimbursement for 340B accounts will rise to ASP + 6%, up from the current rate of ASP — 22.5%. Since the largest share of our CINVANTI hospital demand unit sales comes from 340B accounts, we think this new opportunity will assist us in growing unit sales in the Q4 and in 2023. That wraps up my prepared remarks, and I'll now hand the call back over to Barry.
Barry Quart
executiveThanks, John. Back in June, we made public a restructuring effort that involved cutting our workforce by 34% before the year is over. Thanks to that restructuring, along with better gross margin stemming from the shift to large scale manufacturing and additional cost-reduction steps, we anticipate delivering more than $50 million in yearly operating expense savings during 2023. Those lower burn levels, when combined with the private placement financing we announced earlier today, are expected to give us a cash runway extending through 2024 and to put us in a position to reach positive cash flow in 2024. On June 30, 2022, Heron held cash equivalents and short-term investments totaling $83.5 million. After accounting for net proceeds of $75.2 million from the private placement we completed in August 2022, Heron's cash equivalents and short-term investments came to $158.7 million. Burn during Q2 amounted to $28.4 million. Although burn is set to rise in Q3 because of the restructuring, Q4 burn excluding one-time expenses is expected to land at roughly $21 million, and we foresee substantial additional decreases as we move into 2023. Let me spend a moment walking through a handful of the company's main achievements and catalysts. As we covered during Q2, demand units for ZYNRELEF rose 47% versus Q1. Our contract manufacturer has now successfully validated large scale manufacturing for ZYNRELEF, and enrollment is complete in the clinical studies required for submitting sNDA two to further broaden the indications for ZYNRELEF. One goal we fell short on was finishing a business development deal during Q2. Sadly, the timing of business development deals is hard to forecast, yet we remain laser-focused on completing one or more such deals before this year ends. Within every major territory, we are in active discussions with no fewer than one regional company and no fewer than one multinational. In our oncology care franchise, sales grew nicely, which led us to raise full year 2022 guidance to $93 million-$95 million. As John noted, we're quite enthusiastic about the recent CMS reimbursement change for 340B hospitals, which in our view turns CINVANTI into a highly appealing way for those hospitals to produce extra revenue. Slides 24 and 25 carry important safety information regarding ZYNRELEF. Those slides are going to be posted on our website. With that said, we're ready to take questions. Operator?
Brandon Folkes
analystHello, and I appreciate you fielding my inquiries. Congratulations on everything that's been accomplished. I have perhaps just a pair of items for you. Could you discuss the various factors that are expected to bring about positive cash flow in 2024 when we're building our models? Second, regarding the 15 IDNs that are assessing a changeover involving $42 million in EXPAREL business, what criteria are they applying to judge the product? Is it solely the experience of surgeons and patients? And if they do opt to make the change, what's the timeline for that revenue to move over? Does it happen gradually, or do they switch their entire business at some particular date? Thanks.
Barry Quart
executiveThank you, Brandon. I'll ask John to field the second one initially, since it definitely sets up the response to the first.
John Poyhonen
executiveMorning, Brandon. About what you asked regarding those 15 IDNs: usually an assessment window gets established, and it depends on which surgical procedures are involved. A common pattern we observe is that they begin with a lower extremity arthroplasty — TKA, or more accurately, total hip replacement. Beyond that, they typically examine something within small to medium abdominal surgery, such as bariatric procedures. The things they truly focus on are key parameters. Pain reduction across 3 days gets reviewed. They check how opioid usage is affected, and what matters greatly is also time until discharge; those elements are usually — though there could be variations from one IDN to another — what gets looked at most often. As for how long change takes, well, every one of these systems differs somewhat, and certain ones act faster than others. I believe it's visible in the report we gave today, on slide number 13, where in fact, you know, IDN number one had zero market share during Q3 or Q4 of last year yet climbed to 14%, then 41%, by the Q2. Once they begin committing in that manner, things can progress quite rapidly; however, you know, it's definitely a case where we would never anticipate capturing 100% of the EXPAREL business. That, I think, would be, you know, quite uncommon, yet we do feel we can secure a very substantial share of it. I hope that addressed your question.
Barry Quart
executiveThanks, John. So, yeah, let's revisit the elements involved in reaching positive cash flow. Of course, as you know, one factor is lowering the rate at which we're burning cash. Like we said, back in June we completed a restructuring that trimmed roughly 34% of our workforce and removed substantial expenses from our underlying burn. We keep searching for additional ways to operate more efficiently on that front. Another key piece, too, is growing our margin. As we've talked about before, Heron has put a considerable sum of money into transitioning to large scale manufacturing for both CINVANTI and ZYNRELEF. For ZYNRELEF, that work is now finished, and for CINVANTI, we're nearing the conclusion of that same process. We expect to begin selling CINVANTI produced through large scale manufacturing during the Q4; that lifts our margin considerably. Naturally, with growing unit sales, that simply flows down to the bottom line. Also, as you know, across the next two years, we expect to launch HTX-019 as we take that product to market. That presents a very exciting opportunity when it comes to pursuing roughly 500,000 units of oral aprepitant currently in use for PONV. A product administered as an IV push, such as HTX-019, is definitely positioned to capture a meaningful share of that oral market and then grow past it. As we've said in earlier forums, aprepitant has proven to be among the most effective molecules for PONV. With a convenient, simple to use, simple to administer product such as HTX-019, we think it will turn into an extremely important piece of PONV prophylaxis. Could we move on to the following question?
Josh Schimmer
analystThanks a lot for taking the questions. There are a few things I'd like to cover, if that's alright, though perhaps we could begin with how the ZYNRELEF launch is sitting roughly 80% below the point EXPAREL had reached at this same stage. Could you lay out plainly why you believe that is, and whether any particular steps or strategic adjustments have been made to fix it?
Barry Quart
executiveYes. Appreciate that, Josh. It's a good question. As you're aware, during the initial 2 quarters of launch, the very restrictive label held us back considerably. Sadly, we misjudged how willing surgeons would be to prescribe the product outside that narrow label. Market research had suggested the label wouldn't stand in the way of launching the product, yet it actually proved a major obstacle. Clearly, through those first 2 quarters, things moved far more slowly than we'd expected. Then there's COVID's effect, especially with the Omicron wave early this year, just as we were rolling out the broader label and the expansion of covered procedures from roughly 2 million up to more than 7 million. At this stage, I believe we've begun hitting our stride when it comes to getting the product into new institutions, and we're beginning to observe IDNs switching away from EXPAREL, driven both by our clinical data demonstrating ZYNRELEF's superiority over bupivacaine and by the economics tied to ZYNRELEF. Without question, the launch has moved far more slowly than we'd have predicted. Many factors are at play, yet I believe we're now starting to get past a lot of what was holding us back. As mentioned, we expect to file the sNDA two near the close of the year to broaden the indication statement further. Once that wins approval sometime next year, we'll at last be able to pursue the whole market. Between now and then, I think we'll see continued solid growth.
Josh Schimmer
analystUnderstood. Since the narrow label was so apparent, what do you believe caused your market research to overlook a factor that proved to be as evident as that?
Barry Quart
executiveAlright, I'll hand it over to John to provide some perspective here. The surgeons we spoke with during that market research, and there were quite a lot of them, said they felt at ease using a local anesthetic. They grasped the advantages and disadvantages associated with local anesthetics, and they didn't see the label listing three particular procedures as something that would hold them back. One thing we failed to consider in the early days was that we were in fact strengthening the restrictive nature of the label, since we wouldn't allow our sales reps to remain in the OR when a surgeon was using the product off-label. We truly cemented the idea that this product should be used solely for those three indicated procedures. John, I'm not sure whether there's anything further you'd like to add.
John Poyhonen
executiveNo, I believe you captured that quite nicely, Barry. The single item I'd include, simply stemming from what Josh asked at the start, and if you actually examine only the last 2 quarters, since that's the way we're assessing the launch given how restricted the label was when we began. Across those initial 2 quarters following launch, EXPAREL moved a little more than 19,000 units, and from January 1 onward we sold over 21,000. So we feel we're doing considerably better even considering that first label expansion, and we expect that to keep growing once sNDA two gets cleared.
Josh Schimmer
analystUnderstood. There are a few more things I'd like to ask about. First, regarding formulary approvals — from what you've said previously, it seems roughly 700 formularies are still outstanding. How does that compare with your original projections for formulary adoption, and what kind of headway do you anticipate making across that big group of remaining formularies where approval hasn't come through yet?
John Poyhonen
executiveYeah, great question, Josh. The first thing I'd point out is that when we assess an IDN formulary approval, even if that IDN contains 10 or 15 hospital accounts, some of these IDNs only require the system-level sign-off to secure it, and a single approval can cover every hospital under that IDN. So we're likely undercounting somewhat. Certainly the success rate we're seeing is excellent — among accounts evaluating ZYNRELEF, approvals are running above 90%. We'd like the pace to pick up. Looking at our count of ordering accounts, I believe we're tracking where we expected to be on that metric. What we need to do now is drive more usage within those accounts. As I said in my comments, that really hinges on getting surgeons to use ZYNRELEF in additional surgical procedures, thanks to our new label indication. It also means reaching more surgeons inside the accounts we already have. We think that with the 600 accounts that have used or tried ZYNRELEF, 84% of which are already ordering, we've built a solid base of business. Right now we simply need to grow usage at those accounts, and we'll keep adding formulary approvals moving forward.
Josh Schimmer
analystAt this point, for what share of the addressable market do you either already have formulary coverage or a clear path to securing it before the year is out?
John Poyhonen
executiveLooking at that percentage at the start, our target — driven by how many reps we had out in the field — was roughly 65% of the total market. As things stand today, I'd put us, given the formulary coverage we currently hold, at approximately one-third of that. So Josh, we're probably sitting at, let's say, 20%-25% of the opportunity. Our hope is that by year-end we can drive that figure past 30%.
Josh Schimmer
analystThat still sounds like quite a distance left to cover.
John Poyhonen
executiveSure, you know, when it comes to getting all of it fully opened up, definitely. But when you look at how many ordering accounts there are and what kind of business those ordering accounts can bring us, you know, we believe there's going to be meaningful growth going forward. You know, hospitals have a tendency to move at a slow pace and, you know, that's certainly true here just like with any other hospital launch. I think the hospitals that use ZYNRELEF are seeing excellent results with it, and the growth we've seen in units quarter-over-quarter, along with the reorder rate from the hospitals, has shown that.
Josh Schimmer
analystUnderstood. One final question, and I appreciate you humoring such a large number of them. When we consider the opportunity for HTX-019 in PONV, perhaps you could help put that in context for us alongside SUSTOL, CINVANTI, and ZYNRELEF. What market forces and characteristics, you know, could cause this launch to resemble CINVANTI more than SUSTOL or ZYNRELEF?
Barry Quart
executiveJohn, would you like to handle that one?
John Poyhonen
executiveAbsolutely, that's a wonderful question, and the way we see it, this one is going to resemble CINVANTI far more closely, and the main reason is this: when you examine it, first of all, ZYNRELEF is a product that demands a lot of hands-on engagement from a sales standpoint, since we need to go in and train the surgeon along with the support staff on preparing the product and then administering it. Meanwhile, anybody in the OR understands how to give a 30-second IV push. We held an advisory board this past weekend and spoke with orthopedic surgeons regarding HTX-019, and interest ran very high, because their real focus is on getting patients out of the PACU faster and on to discharge, given how many surgical procedures are shifting to outpatient settings. Honestly, HTX-019 is the ideal drug for accomplishing that, since it offers the strongest clinical profile when it comes to cutting down on vomiting and emesis compared with anything else available on the market. From where we sit, we believe our pricing strategy is the right one to enter the market and secure swift access along with swift uptake, because from an in-service standpoint, things will be far, far simpler than what we experienced with ZYNRELEF.
Josh Schimmer
analystGreat. Thanks very much.
John Poyhonen
executiveCertainly.
Analyst
analystThanks a lot for fielding my question. Nick here, filling in for Boris. I've got just a handful of things to ask. To start with, regarding the IDNs that are looking at therapeutic interchange, roughly what duration should we expect for those trials, individually? I recall you saying they might be spread across, say, a couple of different surgeries. Any sense of the timeline, the number of patients required, for instance, and how many surgeries would be needed per indication? And beyond that, is it possible for a hospital or an IDN to opt for therapeutic interchange covering just one surgery, say, or does it have to apply across the board?
Barry Quart
executiveJohn, do you want to handle that one?
John Poyhonen
executiveAbsolutely. The timelines really vary quite a bit. As you mentioned, Nick, it largely hinges on how many surgical procedures they're going to assess. Typically there's a bony model plus a soft tissue one involved in the accounts evaluating this, and it comes down to how many accounts or hospitals inside an IDN might be running it. On the size question, we've observed accounts considering several hundred in order to reach their decision. Others we've seen sit more in the range of 50 of each. It truly varies from one account to the next. Predicting it is difficult, but here's what I can tell you: in Q2, we had the first IDN that genuinely kicked off its evaluation, which I'd say was probably in March. By the time Q2 wrapped up, they'd reached their decision, and it came out positive for ZYNRELEF. In fact, they're now aiming to switch to ZYNRELEF for indicated procedures. When an account goes through that kind of process, my sense is most will want to use ZYNRELEF across a broader set of uses rather than just one surgical procedure. That's really the reason the expanded label matters so much in supporting our strategy.
Analyst
analystQuestion: Thank you, that's helpful. I just want to ask something else about that point. For the remaining IDNs that aren't yet looking at therapeutic interchange, what would need to happen for them to begin that evaluation? Would that depend on something you'd need to handle, or does it mostly just require time on their side?
John Poyhonen
executiveFrom what we're being told, a number of them simply want more familiarity with ZYNRELEF prior to deciding to move that aggressively. Another point I'd mention is that when you examine certain accounts among those 57 IDNs, we already hold 100% market share on branded products, since they either never adopted EXPAREL or had stopped using it already, given the overpromising around duration of therapy, you know. Honestly, I believe it comes down entirely to experience and receiving positive feedback from surgeons and their patients so that it can extend to a much broader label, or instead a much broader set of IDNs thinking about it.
Analyst
analystGreat. Thank you very much.
John Poyhonen
executiveCertainly.
Serge Belanger
analystHi there, good morning. There are a few things I'd like to ask about ZYNRELEF, and then a few regarding the PONV PDUFA that's coming up. Starting with ZYNRELEF, this one's probably for John. You mentioned that unit demand grew to a bit under 13,000 units during Q2. Could you split that out for us between the ASC side and the hospital side? What I'd like to know is whether at this stage you're taking business away from EXPAREL, or if you're actually capturing a portion of the generic bupivacaine market; and then, second, you also brought up the expectation that ZYNRELEF sales would rise 40%-50% versus the prior quarter in Q3. Could you walk through the assumptions behind that, and maybe what you've observed during the first five or six weeks of Q3? Thanks.
John Poyhonen
executiveOkay. On your first question about where the business is originating. At present, roughly 65% is coming from hospitals, with 35% from ASCs; that's measured by ordering account. When you translate that to units, roughly 80% is hospital and 20% is ASCs. I believe that was your initial question, where's the business coming from? It's genuinely coming from both EXPAREL and bupivacaine. As I said in my previous response, there were definitely certain accounts that had never used EXPAREL or had quit using it, and in those we hold a 100% share of the branded product.
Barry Quart
executiveOne thing that has us particularly enthusiastic is that we keep witnessing solid momentum when it comes to bupivacaine as well as the generic cocktails, driven by the better clinical outcomes. There are a few accounts that have been conducting quite thorough assessments of this involving several hundred patients, all done independently by them, and they intend to publish during H2 of this year, which we believe will be very advantageous for us moving ahead. Last, regarding that 40%-50% growth, well, the elective surgery market overall showed some softness across 2022. Of course, we keep seeing strong growth as we move into Q3 with ZYNRELEF, having just strung together back-to-back, you know, our two best weeks ever. You know, we look forward to sustaining that through Q3 and the rest of the year.
Serge Belanger
analystOkay. Regarding the pending PDUFA for the PONV product, I'm not sure whether you've brought this up before, but was a site inspection needed as part of the NDA review, and if so, has it already happened? And second, how much extra marketing spending should we anticipate for this launch? I'm just trying to think through how that might affect OpEx progression in 2023.
Barry Quart
executiveYeah. Thanks, Serge. So this product, a smaller vial of CINVANTI — and as you're aware, we've manufactured and sold more than 2 million vials of CINVANTI so far — did not need an inspection. We're at, you know, the very final phase of the review cycle right now. Nothing suggests that will change. The manufacturer behind HTX-019 also produces CINVANTI. So I'd say that manufacturer has a very substantial track record of being able to make the product, certainly at a bigger vial size. You know, when it comes to sales expenses and expansion, that's really an excellent question, because it points to something we should have emphasized when that question came up earlier — namely, one of the best things about HTX-019 is that it draws on our resources already concentrated in the acute care setting; we don't expect that meaningful extra investment will be needed, since we already have the reps out there, you know, in the field; they're already speaking with surgeons and anesthesiologists, precisely the target audience for HTX-019. It's a perfect segue for them to add this into the bag, as they say, with no significant added cost and with no need for, you know, any major increases in personnel. Very economical, and truly an exciting product when you look at the published data on how effective the molecule can be for PONV. As John mentioned, in today's world, the biggest issue is getting patients out the door, because there isn't enough staff for patients to remain in the PACU. We're seeing, you know, surgeries not being scheduled into the afternoon the way they otherwise might be, because there's concern about lacking staff for recovery. If you can use an easy-to-use, safe product that helps you get patients out the door in the ASC setting, for example, we think this is gonna be extremely attractive.
Serge Belanger
analystI suppose there's one more thing. For this product to be adopted, will it need to go through roughly the same approval path by way of P&T formularies?
Barry Quart
executiveYes, as a hospital product it would definitely still have to be reviewed by a formulary committee within the hospital setting. But then again, the molecule is itself extremely familiar; it's just, you know, a more convenient way to administer something already used in more than 500,000 oral pills for PONV. We will definitely push really hard to secure that acceptance from P&T committees as fast as we can when it comes to launch. In that respect, it's probably most similar to CINVANTI, which did need formulary approval. If you recall, when that product was launched, the process moved along fairly smoothly. Clearly, we captured a big share of the Emend market during the first 2 years after launch.
Serge Belanger
analystThanks for taking the questions.
Barry Quart
executiveYeah, certainly.
Barry Quart
executiveAppreciate it. I want to thank all of you for being with us on today's call; the advances we made during this quarter have us genuinely encouraged, and we're eager to continue sharing updates with you.
Operator
operatorEveryone, that brings us to the end of today's call. We appreciate you joining us. You're free to hang up at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Heron Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Heron Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Heron Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.